To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Princeton-based Amicus has a ...
More than 200 women lawmakers have signed an amicus brief backing the legal defense to "save women's sports" ahead of next week's Supreme Court oral arguments for two cases related to the issue. The ...
Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease candidate it had once hoped would become a best-in-class treatment. The oral ...
BioMarin BMRN2.49%increase; green up pointing triangle Pharmaceutical has struck a deal to buy fellow biotech Amicus Therapeutics FOLD 0.00%increase; green up pointing triangle for about $4.8 billion ...
Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN.O), opens new tab said on Friday it would acquire Amicus Therapeutics (FOLD.O), opens new tab for about $4.8 billion, in the drugmaker's second deal ...
Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus Therapeutics, a company whose two commercialized products each offer ...
BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, expanding its presence in rare metabolic diseases. The drugmaker will pay $14.50 per share for ...
Sixteen months after luring former Roche dealmaker James Sabry, M.D., Ph.D., out of retirement and signaling a shift in its business development approach, BioMarin has announced the largest ...
The all-cash acquisition price translates to $14.50 per share, valuing the offer at a 33% premium to Amicus's last close, a 46% premium to its 30-day average price, and a 58% premium to its 60-day ...
SAN RAFAEL, Calif., and PRINCETON, N.J., Dec. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
・The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday. ・Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results